Lukas C. Heukamp

17.2k total citations
175 papers, 6.1k citations indexed

About

Lukas C. Heukamp is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Lukas C. Heukamp has authored 175 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Molecular Biology, 81 papers in Pulmonary and Respiratory Medicine and 62 papers in Oncology. Recurrent topics in Lukas C. Heukamp's work include Lung Cancer Treatments and Mutations (60 papers), Cancer Genomics and Diagnostics (25 papers) and Epigenetics and DNA Methylation (19 papers). Lukas C. Heukamp is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Cancer Genomics and Diagnostics (25 papers) and Epigenetics and DNA Methylation (19 papers). Lukas C. Heukamp collaborates with scholars based in Germany, United States and Netherlands. Lukas C. Heukamp's co-authors include Jörg Ellinger, Stefan C. Müller, Patrick J. Bastian, Reinhard Buettner, Alexander von Ruecker, Philip Kahl, Reinhard Büttner, Sebastian Rogenhofer, Johannes H. Schulte and Angelika Eggert and has published in prestigious journals such as Cell, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Lukas C. Heukamp

171 papers receiving 6.0k citations

Peers

Lukas C. Heukamp
Comparison fields: 5 of 123
  • Molecular Biology 3.4k
  • Oncology 1.9k
  • Pulmonary and Respiratory Medicine 1.7k
  • Cancer Research 1.5k
  • Immunology 784
David S. Rickman United States
Oriol Casanovas Spain
Irina Ostrovnaya United States
Maria Cristina Manara Italy
Enrique de Álava Spain
Roland Penzel Germany
Christine Fuller United States
Eric A. Severson United States
Daniel Dumont Canada
Yoon‐La Choi South Korea
David S. Rickman United States View profile →
Citations per field, relative to Lukas C. Heukamp
Lukas C. Heukamp · 1×
Citations per year, relative to Lukas C. Heukamp
Lukas C. Heukamp · 1×

Countries citing papers authored by Lukas C. Heukamp

Since Specialization
Citations

This map shows the geographic impact of Lukas C. Heukamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lukas C. Heukamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lukas C. Heukamp more than expected).

Fields of papers citing papers by Lukas C. Heukamp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lukas C. Heukamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lukas C. Heukamp. The network helps show where Lukas C. Heukamp may publish in the future.

Co-authorship network of co-authors of Lukas C. Heukamp

This figure shows the co-authorship network connecting the top 25 collaborators of Lukas C. Heukamp. A scholar is included among the top collaborators of Lukas C. Heukamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lukas C. Heukamp. Lukas C. Heukamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Title Journal Authors Indexed citations
1 Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients Cancers Stefanie Schmidt, David Horst et al. 1
2 The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations Current Oncology Judith Pirngruber, Eva‐Maria Willing et al. 2
3 BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy European Journal of Cancer Marcel Wiesweg, Martin Metzenmacher et al. 12
4 Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary International Journal of Cancer Tilmann Bochtler, Volker Endris et al. 10
5 Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica Tumori Journal Linda Mahjoubi, Franco Cecchi et al. 0
6 MA04.05 P53 Non-Disruptive Mutation is a Negative Predictive Factor for OS and PFS in EGFR M+ NSCLC Treated with TKI Journal of Thoracic Oncology R. Prenzel, Kay Willborn et al. 2
7 The Prosurvival IKK-Related Kinase IKKϵ Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine Cancer Research Serkan İsmail Göktuna, Kateryna Shostak et al. 19
8 Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer The Journal of Experimental Medicine Sylvain Delaunay, Francesca Rapino et al. 131
9 Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom. Aktueller Stand und Erfahrungen der ersten deutschen Harmonisierungsstudie Der Pathologe Andreas H. Scheel, Manfred Dietel et al. 17
10 NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas International Journal of Cancer Lydia Meder, Katharina König et al. 141
11 Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer Cancer Research Sampurna Chatterjee, Caroline Wieczorek et al. 28
12 A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC Cancer Discovery Felix Dietlein, Lisa Thelen et al. 53
13 Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy Cell Christian P. Pallasch, Ilya Leskov et al. 130
14 Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues Journal of Clinical Pathology Kerstin Becker, Claudia Vollbrecht et al. 7
15 Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer Journal of Clinical Investigation Sampurna Chatterjee, Lukas C. Heukamp et al. 164
16 Mast cells play a protumorigenic role in primary cutaneous lymphoma Blood Anja Rabenhorst, Max Schlaak et al. 105
17 Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants Clinical Cancer Research Johannes M. Heuckmann, Hyatt Balke‐Want et al. 201
18 ALK(F1174L) is a driving oncogene of neuroblastoma in transgenic mice Pediatric Blood & Cancer Johannes H. Schulte, Lukas C. Heukamp et al. 1
19 Pharmacological activation of the p53 pathway by nutlin-3 inhibits medulloblastoma cell proliferation in vitro and in vivo European Journal of Pediatrics Annette Künkele, Katleen De Preter et al. 1
20 Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin The Journal of Immunology Thorbald van Hall, Jeroen van Bergen et al. 38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David S. Rickman Breakdown of academic impact, for papers by Oriol Casanovas Breakdown of academic impact, for papers by Irina Ostrovnaya Breakdown of academic impact, for papers by Maria Cristina Manara Breakdown of academic impact, for papers by Enrique de Álava Breakdown of academic impact, for papers by Roland Penzel Breakdown of academic impact, for papers by Christine Fuller Breakdown of academic impact, for papers by Eric A. Severson Breakdown of academic impact, for papers by Daniel Dumont Breakdown of academic impact, for papers by Yoon‐La Choi
Rankless by CCL
2026